A retrospective study evaluating the feasibility and safety outcomes outpatient practice and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma
Latest Information Update: 31 Jul 2021
Price :
$35 *
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- 31 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology